Publications by authors named "Thor Ameri Chalmer"
Article Synopsis
- - The study aimed to compare the effectiveness of high-efficacy disease-modifying therapies (heDMTs) and medium-efficacy disease-modifying therapies (meDMTs) in patients with multiple sclerosis (MS) who have not previously received treatment, focusing on disability worsening and relapse rates.
- - Researchers analyzed data from the Danish Multiple Sclerosis Registry, assessing a total of 388 patients, with findings showing that those on heDMT had significantly lower rates of disability worsening and first relapses compared to those on meDMT over a 4-year period.
- - The conclusion indicates that starting treatment with heDMT is associated with a reduced risk of deterioration in disability and fewer relapses in MS patients, providing Class
Background: Some patients with multiple sclerosis who are treated with interferon-β(IFNβ) develop neutralizing antibodies (NAbs), which reduce or abolish the therapeutic effects of the treatment. These patients are usually switched to a non-IFNβ treatment, such as glatiramer acetate (GA). It is unknown whether a patient's previous disease activity in combination with their NAb-status can provide further insights on their risk of future disease activity.
View Article and Find Full Text PDFObjective: To assess the risk of losing income from salaries and risk disability pension for multiple sclerosis patients with a clinically stable disease course 3 years after the start of disease-modifying therapy (DMT).
Methods: Data from the Danish Multiple Sclerosis Registry were linked to other Danish nationwide population-based databases. We included patients who started treatment with a DMT between 2001 and 2014.
Background: Disease-modifying therapies (DMT) are increasingly used for children with multiple sclerosis (MS) even though most double-blinded randomized controlled trials evaluating efficacy, safety and dosing strategy of a specific drug have included adults.
Objective: To investigate predictors of treatment outcomes in patients with paediatric onset MS treated with DMTs.
Methods: Prospective cohort study from the nationwide Danish Multiple Sclerosis Registry including all patients with a MS diagnosis who initiated treatment with an approved DMT before the age of 18 ( = 137) and followed until their 25th birthday.
Objective: To compare on-treatment efficacy and discontinuation outcomes in teriflunomide (TFL) and dimethyl fumarate (DMF) in the treatment of relapsing-remitting multiple sclerosis (RRMS) in a real-world setting.
Methods: We identified all patients starting TFL or DMF from the Danish Multiple Sclerosis Registry and compared on-treatment efficacy outcomes between DMF using TFL, adjusted for clinical baseline variables and propensity score-based methods.
Results: We included 2,236 patients in the study: 1,469 patients on TFL and 767 on DMF.
Background: Patients with multiple sclerosis who experience disease breakthrough often switch disease-modifying therapy (DMT).
Objective: To compare treatment effectiveness of switch to highly effective DMT (heDMT) with switch to moderately effective DMT (meDMT) for patients who switch due to disease breakthrough defined as at least one relapse within 12 months of their treatment switch.
Methods: We retrieved data from The Danish Multiple Sclerosis Registry on all relapsing-remitting MS patients with expanded disability status scale (EDSS) less than 6 who experienced disease breakthrough.